Miniature Human Hearts Offer Hope in 30-Year Fight Against Atrial Fibrillation
Table of Contents
A groundbreaking development from Michigan State University offers the first critically important leap forward in atrial fibrillation (A-fib) treatment in three decades, thanks to the creation of remarkably accurate, miniature human heart models known as organoids.
An estimated 60 million people worldwide suffer from A-fib, a type of irregular and frequently enough rapid heartbeat. For years, progress in developing new treatments has stalled due to the lack of reliable models to study the complex human heart. now, scientists have overcome this hurdle, paving the way for accelerated drug development and improved patient outcomes.
The Rise of ‘Heart-in-a-Dish’ Technology
In 2020, a team led by Michigan State University researcher Aitor Aguirre began perfecting these tiny, three-dimensional heart organoids. These “hearts-in-a-dish,” roughly the size of a lentil, are so physiologically accurate that they allow researchers to study heart development, disease mechanisms, and drug responses in ways previously unimaginable. Remarkably, the organoids exhibit a strong, visible rhythmic beating even without the aid of a microscope.
“This is the first time we’ve been able to study living human heart tissue directly, something that hasn’t been possible before,” O’Hern explained. “When we added inflammatory molecules, the heart cells began beating irregularly. Then we introduced an anti-inflammatory drug, and the rhythm partially normalized. It was amazing to see that happen.”
Breaking a Three-Decade Treatment Drought
The lack of effective animal models has historically hampered therapeutic drug development for A-fib. Current treatments often focus on managing symptoms rather than addressing the underlying causes of the condition.
“This new model can replicate a condition that is at the core of many people’s medical problems,” Aguirre added. “It’s going to enable a lot of medical advances so patients can expect to see accelerated therapeutic developments, more drugs moving into the market, safer drugs and cheaper drugs, too, because companies are going to be able to develop more options.”
The study also revealed that long-lived immune cells residing within specific organs guide heart development and rhythm. This insight extends to understanding the origins of congenital heart disorders, the most common type of birth defect. Researchers further refined the model by “aging” the organoids, exposing them to inflammation to mirror the conditions that lead to A-fib in adult hearts. Testing an anti-inflammatory drug on these aged organoids successfully restored a normal heart rhythm, demonstrating the model’s potential for therapeutic screening.
A New Era of Heart Research and Personalized Medicine
Aguirre emphasized that the addition of immune cells significantly enhances the physiological accuracy of the models. “We’re now seeing how the heart’s own immune system contributes to both health and disease,” he saeid.”This gives us an unprecedented view of how inflammation can drive arrhythmias and how drugs might stop that process.”
The development of this human heart organoid model is poised to overcome the 30-year stagnation in A-fib treatment. Aguirre’s work aligns with the National Institutes of Health’s mission to modernize translational research and improve the predictability of preclinical testing.
MSU researchers are already collaborating with pharmaceutical and biotech companies to screen potential compounds, ensuring they don’t cause heart damage while effectively preventing arrhythmia. Looking ahead, Aguirre’s team envisions developing personalized heart models derived from individual patient cells for precision medicine and, ultimately, generating transplant-ready heart tissues.
The research team included contributions from Christopher Contag, Nureddin Ashammakhi, and Sangbum Park from the MSU Institute for quantitative Health Science and Engineering; Nagib Chalfoun from Corewell Health; and Chao Zhou from Washington University.
more details: Colin O’Hern et al, human heart-macrophage assembloids mimic immune-cardiac interactions and enable arrhythmia disease modeling, Cell Stem Cell (2025). DOI: 10.1016/j.stem.2025.09.011.
